What the FDA's accelerated approval of a new Alzheimer's drug could mean for those with the disease – 5 questions answered about lecanemab
- Written by James E. Galvin, Professor of Neurology, University of Miami
Alzheimer's disease is an incapacitating, progressive brain disorder that affects the lives of more than 6.5 million Americans. PamelaJoeMcFarlane/E+ via Getty ImagesThe U.S. Food and Drug Administration approved the medication lecanemab, sold under the brand name Leqembi, on Jan. 6, 2023, through an “accelerated approval pathway” that...

